Pay in 4 interest-free payments of $5.70 Learn more
Ships within 48 hours · Estimated delivery Aug 22 - Aug 27
Previous research has already suggested GLP-1 agonists may increase or decrease the risk of many of the diseases included in this study
In STEP 1, 1,961 nondiabetic adults with overweight or obesity achieved an average 14.9% weight loss over 68 weeks when semaglutide was combined with lifestyle changes.20 STEP 2 examined 1210 individuals with T2DM and showed a more modest average weight loss of 9.6%, possibly due to insulin resistance and the influence of other diabetes medications.21 STEP 3 introduced a more intensive lifestyle intervention to participants who were overweight or obese but without T2DMincluding a calorie-restricted diet and behavioral supportand resulted in slightly higher weight loss amongst the 611 study participants, averaging around 16%.22 The STEP 4 trial included 811 individuals who were overweight or obese without diabetes and assessed the impact of discontinuing semaglutide after 20 weeks
Anderson SL, Greenway FL, Fujioka K
L., Glatt, S
US$ 22.84
US$ 28.75
US$ 28.41
US$ 22.85
US$ 20.59
